Proliferation marker Ki-67 in early breast cancer.
暂无分享,去创建一个
[1] S. Hilsenbeck,et al. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] M. J. van de Vijver,et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[3] H. Rochefort,et al. The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor , 1984, Molecular and Cellular Endocrinology.
[4] R. Broll,et al. Colorectal carcinomas with high MIB‐1 labelling indices but low pKi67 mRNA levels correlate with better prognostic outcome , 2003, Histopathology.
[5] W. Weikel,et al. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. , 1995, Cancer detection and prevention.
[6] T. Powles,et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] I. Kill. Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. , 1996, Journal of cell science.
[8] A. Antón,et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] M. Fernö,et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node‐negative breast cancer , 2003, International journal of cancer.
[10] S. Chevillard,et al. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer , 2005, Breast Cancer Research and Treatment.
[11] K. Zedeler,et al. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas , 2005, Breast Cancer Research and Treatment.
[12] M. Dowsett,et al. Preoperative chemotherapy induces apoptosis in early breast cancer , 1997, The Lancet.
[13] G. Hortobagyi,et al. Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis , 1991, Cancer.
[14] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Gelber,et al. Ki‐67 expression in breast carcinoma , 2003, Cancer.
[16] M. Mitze,et al. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67 , 1991, Breast Cancer Research and Treatment.
[17] F Pozza,et al. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. , 1991, Anticancer research.
[18] M. Dowsett,et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[20] T. Powles,et al. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. , 1996, British Journal of Cancer.
[21] S. Bruno,et al. Cell cycle dependent expression and stability of the nuclear protein detected by Ki‐67 antibody in HL‐60 cells , 1992, Cell proliferation.
[22] L. Skoog,et al. Prognostic Significance of Tumor Cell Proliferation Analyzed in Fine Needle Aspirates from Primary Breast Cancer , 2004, Breast Cancer Research and Treatment.
[23] M. Dowsett,et al. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. , 1999, Cancer research.
[24] T. Powles,et al. Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer , 2003, Breast Cancer Research and Treatment.
[25] W. Weikel,et al. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. , 1995, Gynecologic oncology.
[26] R. Jakesz,et al. Expression of Cell Cycle Regulatory Proteins in Breast Carcinomas Before and After Preoperative Chemotherapy , 2003, Breast Cancer Research and Treatment.
[27] M. Dowsett,et al. The biology of neoadjuvant chemotherapy for breast cancer. , 2002, Endocrine-related cancer.
[28] F. Spyratos,et al. Correlation between MIB‐1 and other proliferation markers , 2002, Cancer.
[29] G. Pelosi,et al. Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis , 1997, International journal of cancer.
[30] C. Cornelisse,et al. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. , 1989, Cancer research.
[31] A. Howell,et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. , 1997, Cancer research.
[32] M. Dowsett,et al. Time‐related effects of estrogen withdrawal on proliferation‐ and cell death‐related events in MCF‐7 xenografts , 1999, International journal of cancer.
[33] A. Thor,et al. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] J. Sloane,et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. , 1999, The American journal of pathology.
[35] I. Ellis,et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. , 1995, British Journal of Cancer.
[36] M. Fernö,et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. , 1999, Journal of the National Cancer Institute.
[37] T. Powles,et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma , 2000, Cancer.
[38] C. Bartoli,et al. Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study. , 1998, International journal of oncology.
[39] U. Veronesi,et al. Changes in biological markers after primary chemotherapy for breast cancers , 1995, International journal of cancer.
[40] T. Powles,et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] Johannes Gerdes,et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.
[42] S. Singletary,et al. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] K. Maclennan,et al. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. , 1994, European journal of cancer.
[44] M. Dowsett,et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[45] E. Petru,et al. T1 Breast Cancer: Identification of Patients at Low Risk of Axillary Lymph Node Metastases , 2002, Breast Cancer Research and Treatment.
[46] J. Gerdes,et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[47] A. Luini,et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. , 2003, Journal of the National Cancer Institute.
[48] I. Ellis,et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. , 1993, European journal of cancer.
[49] B. Iacopetta,et al. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] G. Giaccone,et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy , 1997, International journal of cancer.
[51] V. Kosma,et al. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.
[52] M. Dowsett,et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy , 1998, Breast Cancer Research and Treatment.
[53] M. Starborg,et al. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. , 1996, Journal of cell science.
[54] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] M. Gnant,et al. Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis , 2004, Breast Cancer Research and Treatment.
[56] M. Dowsett,et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[57] T. Powles,et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response , 1998, Breast Cancer Research and Treatment.
[58] M. J. van de Vijver,et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.
[59] M. Ellis,et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. , 2003, Cancer research.
[60] L. Skoog,et al. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. , 1999, Acta oncologica.
[61] P. Boracchi,et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. , 1992, British Journal of Cancer.
[62] M. Dowsett,et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. , 2001, Cancer research.
[63] P. Bruzzi,et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer , 2001, British Journal of Cancer.
[64] M. Hidalgo,et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[65] M. Dowsett,et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] T. Venesio,et al. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. , 1993, European journal of cancer.
[67] K. Sasaki,et al. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Comparison with DNA ploidy. , 1992, Oncology.
[68] Mikael Lundin,et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] G. Brugal,et al. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. , 1991, Cytometry.
[71] H. Müller-Hermelink,et al. Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.
[72] H. Hara,et al. Proliferation marker MIB‐1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c‐erbB‐2 and estrogen receptor status , 1996, Pathology international.
[73] K. Sasaki,et al. Relationship between labeling indices of KI‐67 and brdurd in human malignant tumors , 1988, Cancer.
[74] N. Bundred,et al. Short‐term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma , 2003, Cancer.
[75] V. Jordan,et al. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. , 2003, European journal of cancer.
[76] J. Schulte‐Mönting,et al. Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.
[77] P. Lønning,et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[78] M. Fernö,et al. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. , 2001, Human pathology.
[79] J. Gerdes,et al. Assignment of the human Ki-67 gene (MKI67) to 10q25−qter , 1991 .
[80] R. Parwaresch,et al. Monoclonal antibodies Ki‐S3 and Ki‐S5 yield new data on the ‘Ki‐67’proteins , 1996, Cell proliferation.
[81] J. Horiguchi,et al. A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer. , 2000, International journal of oncology.
[82] C. Osborne,et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] M. Fernö,et al. Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications , 1999, The Journal of pathology.
[84] Michael A. Gonzalez,et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] I. Ellis,et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. , 1989, British Journal of Cancer.
[86] I. Ellis,et al. Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer , 2004, Breast Cancer Research and Treatment.
[87] M. Dowsett,et al. Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer , 2001 .
[88] A. Howell,et al. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. , 1993, British Journal of Cancer.
[89] P. Lipponen. Apoptosis in breast cancer: relationship with other pathological parameters. , 1999, Endocrine-related cancer.
[90] D. Horsfall,et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.
[91] T. Petit,et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. , 2004, European journal of cancer.
[92] F. Lacombe,et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. , 1991, Cytometry.
[93] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[94] M. Dowsett,et al. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[95] A. Thor,et al. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] J. Gerdes,et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. , 1991, The American journal of pathology.
[97] M. Dowsett,et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[98] S. Nordling,et al. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. , 1997, Acta oncologica.
[99] A. Howell,et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. , 1994, Cancer research.
[100] M. Dowsett,et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. , 2002, Anticancer research.
[101] M. Key,et al. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[102] E. Prosperi. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. , 1997, Progress in cell cycle research.
[103] J. Gerdes,et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins , 1993, The Journal of cell biology.